BACKGROUND: The aim of this study was to determine the prognostic role for survival of thyroid transcription factor 1 (TTF-1) in lung cancer. METHODS: Studies evaluating survival and TTF-1 in lung cancer patients, published until August 2005, were assessed with a methodological scoring system. The required data for estimation of individual hazard ratios (HRs) for survival were extracted from the publications and a combined HR was calculated. RESULTS: We identified 10 eligible papers, all dealing with non-small-cell lung cancer (NSCLC). Eight were meta-analysed (evaluable studies). Seven studies included patients with local and/or locoregional diseases and three dealt only with adenocarcinoma. Median methodological quality score was 65.9% (range = 31.8%-70.5%). TTF-1 positivity was associated with statistically significant reduced or improved survival in one and four studies, respectively. Combined HR for the eight evaluable studies was 0.64 [95% confidence interval (CI) = 0.41-1.00]. In the subgroup of adenocarcinoma, the combined HR was 0.53 (95% CI = 0.29-0.95). CONCLUSION: TTF-1 is a good prognostic factor for survival in NSCLC. Its effect appears also significant when the analysis is restricted to patients with adenocarcinoma. This study supports the fact that TTF-1 could be included in further prospective trials studying prognostic factors in NSCLC.
BACKGROUND: The aim of this study was to determine the prognostic role for survival of thyroid transcription factor 1 (TTF-1) in lung cancer. METHODS: Studies evaluating survival and TTF-1 in lung cancerpatients, published until August 2005, were assessed with a methodological scoring system. The required data for estimation of individual hazard ratios (HRs) for survival were extracted from the publications and a combined HR was calculated. RESULTS: We identified 10 eligible papers, all dealing with non-small-cell lung cancer (NSCLC). Eight were meta-analysed (evaluable studies). Seven studies included patients with local and/or locoregional diseases and three dealt only with adenocarcinoma. Median methodological quality score was 65.9% (range = 31.8%-70.5%). TTF-1 positivity was associated with statistically significant reduced or improved survival in one and four studies, respectively. Combined HR for the eight evaluable studies was 0.64 [95% confidence interval (CI) = 0.41-1.00]. In the subgroup of adenocarcinoma, the combined HR was 0.53 (95% CI = 0.29-0.95). CONCLUSION:TTF-1 is a good prognostic factor for survival in NSCLC. Its effect appears also significant when the analysis is restricted to patients with adenocarcinoma. This study supports the fact that TTF-1 could be included in further prospective trials studying prognostic factors in NSCLC.
Authors: Kyuichi Kadota; Jun-Ichi Nitadori; Inderpal S Sarkaria; Camelia S Sima; Xiaoyu Jia; Akihiko Yoshizawa; Valerie W Rusch; William D Travis; Prasad S Adusumilli Journal: Cancer Date: 2012-10-23 Impact factor: 6.860
Authors: B S Sheffield; I E Bosdet; R H Ali; S S Young; B K McNeil; C Wong; K Dastur; A Karsan; D N Ionescu Journal: Curr Oncol Date: 2014-12 Impact factor: 3.677
Authors: Carmen Behrens; Luisa M Solis; Heather Lin; Ping Yuan; Ximing Tang; Humam Kadara; Erick Riquelme; Hector Galindo; Cesar A Moran; Neda Kalhor; Stephen G Swisher; George R Simon; David J Stewart; J Jack Lee; Ignacio I Wistuba Journal: Clin Cancer Res Date: 2013-10-04 Impact factor: 12.531
Authors: Eric L Snyder; Hideo Watanabe; Margaret Magendantz; Sebastian Hoersch; Tiffany A Chen; Diana G Wang; Denise Crowley; Charles A Whittaker; Matthew Meyerson; Shioko Kimura; Tyler Jacks Journal: Mol Cell Date: 2013-03-21 Impact factor: 17.970
Authors: Narasimhan Kothandaraman; Vladimir B Bajic; Pang N K Brendan; Chan Y Huak; Peh B Keow; Khalil Razvi; Manuel Salto-Tellez; Mahesh Choolani Journal: BMC Cancer Date: 2010-02-24 Impact factor: 4.430